Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Stock Code: 02196) released its 2025 third quarter report. According to the announcement, operating revenue for the first three quarters reached RMB29,393 million, representing a 4.91% decrease year-on-year. Revenue in the third quarter alone was RMB9,879 million, down 5.46% compared with the same period last year. The company’s net profit attributable to shareholders for the first three quarters stood at RMB2,523 million, reflecting a year-on-year increase of 25.50%. Meanwhile, net profit after deducting extraordinary gains or losses was RMB1,573 million.
The announcement mentioned that gains from disposing of equity interests in non-core assets were a key factor contributing to overall net profit growth. However, revenues for certain products were affected by the renewal of national volume-based procurement contracts. Research and development investment totaled RMB3,998 million during the first three quarters, with R&D expenses of RMB2,730 million, up 3.08% year-on-year.
During the reporting period, the company continued to advance its innovative drug and high-end medical device pipeline. Fovinaciclib Citrate Capsules (Fu Tuo Ning) received an additional approval for treating HR-positive, HER2-negative breast cancer in mainland China. Denosumab Injection (HLX14) obtained approvals in the United States and the European Union. Brexucabtagene Autoleucel Injection submitted a drug registration application for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in mainland China.
The announcement also highlighted ongoing share repurchase plans and a second issuance of scientific and technological innovation bonds, amounting to RMB1 billion at an interest rate of 2.70%. The 2025 A Share Option Incentive Scheme and a 2025 H Share Restricted Share Unit scheme were approved, aiming to attract and retain key talent. The company’s operating cash flow remained robust, reaching RMB3,382 million in the first three quarters, representing a 13.23% increase year-on-year.